TickerFacts.

Company research / BCRX

BioCryst Pharmaceuticals Inc (BCRX)

Build a valuation ↗↓ Download CSV

SEC name BIOCRYST PHARMACEUTICALS INC · CIK 0000882796 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, BioCryst Pharmaceuticals Inc reported revenue of $874.84M. Revenue grew 94.1% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $940.61M.

Key ratios (year ended 2025-12-31)

39.0%
Operating margin
30.2%
Net margin
94.1%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-09-02

Headquarters locality: Durham · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$940.61M$874.84M$450.71M$331.41M$270.83M$157.17M$17.81M$48.84M$20.65M$25.19M$26.35M
Cost of Revenue$20.93M$19.07M$12.27M$4.48M$6.41M$7.23M$1.55M$3.73Mn/a$1.14M$2.30M
Gross Profit (computed)n/an/an/an/an/an/a$16.26M$45.11Mn/an/a$24.06M
R&D Expense$197.76M$166.13M$174.64M$216.57M$253.30M$208.81M$122.96M$107.07M$84.89M$66.96M$61.01M
Operating Income-$313.16M$340.99M-$2.54M-$103.71M-$148.44M-$177.72M-$174.76M-$99.45M-$94.22M-$57.41M-$48.61M
Depreciation & Amortizationn/a$1.39M$1.25M$1.66M$1.44M$777.0K$748.0K$724.0K$770.0K$704.0K$483.0K
EBITDAn/a$342.38M-$1.30M-$102.05M-$147.00M-$176.94M-$174.01M-$98.73M-$93.45M-$56.71M-$48.12M
Net Income-$384.67M$263.86M-$88.88M-$226.54M-$247.12M-$184.06M-$182.81M-$108.90M-$101.25M-$65.78M-$55.14M
EPS (Diluted)n/a$1.21-$0.43-$1.18-$1.33-$1.03-$1.09n/an/an/an/a
Total Assets$557.85M$514.16M$490.42M$516.96M$550.00M$588.15M$334.71M$175.28M$146.84M$178.26M$89.85M
Total Liabilities$1.01B$633.31M$966.35M$972.49Mn/an/an/an/an/an/an/a
Long-Term Debtn/an/an/an/an/a$298.14M$122.61M$50.00M$30.00M$23.00M$23.00M
Shareholders' Equity-$454.29M-$119.15M-$475.93M-$455.53M-$294.60M-$106.99M-$19.26M$38.25M$49.23M$83.77M$1.58M
Cash & Equivalents$154.97M$89.74M$104.71M$110.64M$304.77M$504.39M$272.13M$114.17M$26.73M$50.28M$22.10M
Operating Cash Flow$376.13M$347.37M-$52.02M-$95.14M-$161.85M-$142.16M-$135.11M-$89.58M-$92.56M-$41.14M-$53.44M
Capital Expenditures$2.76M$2.47M$1.12M$2.17M$1.35M$2.38M$514.0K$343.0K$366.0K$328.0K$5.28M
Free Cash Flow$373.38M$344.90M-$53.14M-$97.31M-$163.20M-$144.54M-$135.62M-$89.93M-$92.93M-$41.47M-$58.72M
Shares Outstanding255.26M213.06M208.54M205.77M187.91M184.35M176.88M154.08M110.06M98.41M73.78M
Weighted Average Diluted Sharesn/a218.58M206.70M192.20M185.91M179.12M167.27M115.60M103.19M84.45M73.70M
EPS (Basic)n/a$1.26-$0.43-$1.18-$1.33-$1.03-$1.09n/an/an/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView